NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
Makoto Maemondo(Miyagi Prefectural Hospital Organization), T. Nukiwa(Tohoku University), Akihiko Gemma(Nippon Medical School), Yuichi Takiguchi(Sanno Medical Center), Kunihiko Kobayashi(Saitama International Medical Center), Akira Inoue(Tohoku University Hospital), Satoshi Oizumi(Hokkaido University), Tomohiko Isobe(National Institute for Environmental Studies), H. Yoshizawa, Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Yoshiki Ishii(Dokkyo Medical University), Satoshi Morita(Kyoto University), Koichi Hagiwara(Jichi Medical University)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695